Abstract 1865P
Background
This study aimed to determine how the chemotherapy process can lead to a change in self-esteem in elderly patients with early-stage breast cancer according to personality type.
Methods
The research was completed as a pilot study between 2019-2022. Female patients aged 65 and over who were planned for adjuvant treatment were included in the study. Personality type and self-esteem were determined in all patients before and after adjuvant chemotherapy. Bortner Rating Scale was used to determine personality type, and Rosenberg Self-Esteem Scale was used to determine self-confidence. Paired t-test was performed for recurrent variables in pre-treatment and post-treatment measures. Multivariate logistic (binary) regression analysis was performed to determine the independent factors affecting low self-esteem from the study variables with the model created as a result of correlation and univariate analysis. Statistical analysis was performed using the SPSS v19 program and a p value of <0.05 was considered statistically significant.
Results
A total of 69 Her2-negative elderly female patients were included in this pilot study. The mean age of the patients was 68 years (65-72). 54% had radical mastectomy. 69% received paclitaxel for 12 weeks, 21% received 6x DC, and 10% received 3x CEF followed by 3x docetaxel for adjuvant setting. 56% of them had personality type A. Before treatment, 62% had high self-esteem and this was significantly higher in type A personality than in type B (84% vs 48%, respectively; p=0.037). While the rate of high self-esteem decreased in type A personality after treatment (p=0.009), there was no change in type B personality (p=0.379). It was determined that type A personality structure was independent affecting low self-esteem after treatment (OR 5.37 95%CI 1.489-9.396; p=0.006).
Conclusions
In this study, it was concluded that elderly women with type A personality structure may be more sensitive and may have low self-esteem after the treatment is completed. It was concluded that the personality type should be guided by the patient's treatment compliance, need for psychosocial support, and coping methods after the completion of the treatment, supported by the physician.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics committee approval could not be obtained because it was a pilot study. In the follow-up research, the results of the pilot study will be declared and consent will be obtained.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05